Galencia says earnings growth around 40%

Swiss pharmaceutical firm Galencia is predicting double-digit earnings growth for the full-year 2008 of around 40% up on the previous year. The  company confirms its final sales figure will be up 6.9% on that for  2007, reaching 2.7 billion Swiss francs ($2.39 billion). The firm's  recently-created pharmaceutical subsidiary, formed during Galencia's  acquisition of Canadian firm Aspreva in 2007, will see sales that have  risen 8.4% to 433.9 million francs. The company's health care  information revenue was up 17.3% to 41.5 million francs, whereas  turnover from its logistics and retail divisions increased 3% to 2.03  billion francs and 29.9% to 557.1 million francs, respectively. Full  figures will be released on March 17.